Media reports alleging Centre hasn't placed any fresh order for Covid-19 vaccines incorrect: Health ministry
"The news reports suggest that the last order placed with the two vaccine makers (100 million doses with SII and 20 million doses with Bharat Biotech) was in March 2021. These media reports are completely incorrect, and are not based on facts," the ministry said in a statement.
You Might Like
💡 newsR Knowledge: Other News Mentions
Boris Johnson: We must be 'cautious' over June 21 lockdown easing
Credit: PA - Press Association STUDIO Duration: 00:26Published
States record Covid toll as per ICMR: Centre on 'speculative' report that India suffered 5-7 times excess deaths
Oxford vaccine scientists honoured for 'high-stakes endeavour'
Credit: PA - Press Association STUDIO Duration: 02:50Published
Covishield produces more antibodies than Covaxin, finds studyCovishield, from the Oxford-AstraZeneca stable, is manufactured by the Serum Institute of India in Pune. Covaxin is the indigenously manufactured vaccine by..
COVID-19: DCGI approves Serum Institute to manufacture Sputnik V vaccine in IndiaSII has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow in Russia for developing Sputnik V.
US to ease Covid vaccine input supply: Kamala Harris to PM ModiUS Vice-President Kamala Harris on Thursday spoke to PM Narendra Modi to brief him about the Biden administration’s new vaccine policy that will clear supply..
Ocugen to seek emergency nod for Covaxin from Health CanadaBharat Biotech’s US partner Ocugen said it will be seeking an emergency use nod for India’s first indigenously developed Covid-19 vaccine Covaxin from the..
Ocugen to seek full approval for Covaxin in US via BLA instead of EUABharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be..
Ocugen to take BLA route for Covaxin in US based on FDA recommendation; seek emergency use nod for CanadaBharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be..
Brazil regulator grants GMP certification to Bharat Biotech's Covaxin facilitiesLess than a week after Brazil’s health regulator green-lighted the “exceptional import” of 4 million doses of Bharat Biotech’s Covid-19 jab Covaxin, it..
Related videos from verified sources
Related news from verified sources